LAKE FOREST, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.62 per share for gross proceeds of approximately $14.0 million.
Roth Capital Partners acted as the sole placement agent in connection with the offering. After the placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $13.0 million.
The Company intends to use the net proceeds from the offering for general corporate purposes, including general working capital.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Assertio
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital and pain and inflammation. Assertio has grown through business development including licensing, mergers and acquisitions.
Investor Contact
Max Nemmers
[email protected]
SOURCE Assertio Holdings, Inc.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
